Sure unwanted side effects following enfortumab vedotin related to improved PFS in metastatic urothelial carcinoma: © magicmine – inventory.adobe.com
For sufferers with metastatic bladder or higher tract urothelial carcinoma who had been handled with Padcev (enfortumab vedotin, EV), the presence of neuropathy, pores and skin rash or hyperglycemia was related to improved progression-free survival (PFS), in response to analysis revealed in a poster on the 2025 ASCO Genitourinary Cancers Symposium.
Glossary:
Hyperglycemia: excessive blood glucose ranges, typically on account of diabetes or therapy unwanted side effects.
Development-free survival (PFS): time a affected person lives with out illness development.
General survival (OS): time from prognosis or therapy to dying from any trigger.
After a median follow-up of 14 months from the beginning of Padcev, neuropathy was reported in 30 sufferers (36%), pores and skin rash in 32 sufferers (39%) and hyperglycemia in six sufferers (7%). The median PFS was 4.5 months in sufferers who didn’t expertise neuropathy, pores and skin rash or hyperglycemia; 10.6 months in these with neuropathy; 8.6 months in these with pores and skin rash; and 15.9 months in these with hyperglycemia.
Between 2018 and 2024, a complete of 83 sufferers had been handled with not less than two doses of Padcev. Of those, 47 sufferers acquired Padcev plus Keytruda (pembrolizumab) and 36 sufferers acquired Padcev as a single agent. The median age was 69 years. Metastatic websites included lymph nodes (42 [50%]), lungs (34 [41%]), bones (29 [35%]), liver (16 [19%]) and mind (7 [8%]). Padcev was used as first-line remedy in 43 (52%) sufferers, as second-line remedy in 28 (34%), as third-line remedy in 10 (12%) and as fourth-line remedy in 2 (2%).
Using a question of the Indiana College bladder most cancers database, investigators recognized sufferers with domestically superior and metastatic bladder and higher tract urothelial carcinoma handled with Padcev with or with out pembrolizumab. Sufferers with variant histology had been included. Toxicities had been documented all through therapy. The affiliation of neuropathy, pores and skin rash, and hyperglycemia with PFS was in contrast with that of sufferers with out these unwanted side effects (SE) utilizing the log-rank take a look at.
“Neuropathy, pores and skin rash, and hyperglycemia are widespread antagonistic occasions related to Padcev, in response to research authors,” first research writer Dr. Tareq Salous and authors wrote within the summary of the research.
Salous is an assistant professor of medical drugs within the Division of Medication, Division of Hematology/Oncology, on the Indiana College (IU) Faculty of Medication, IU Simon Complete Most cancers Heart, and is an affiliate member of Experimental and Developmental Therapeutics, in Indianapolis.
In response to the Nationwide Most cancers Institute’s web site, neuropathy is a nerve dysfunction inflicting ache, numbness, tingling, swelling or muscle weak point in varied physique elements, typically beginning within the fingers or ft and worsening over time. It might probably outcome from most cancers or most cancers remedies like chemotherapy, in addition to bodily damage, an infection, toxins or situations corresponding to diabetes, kidney failure or malnutrition. That is also referred to as peripheral neuropathy.
Moreover, additionally in reference to the Nationwide Most cancers Institute’s web site, urothelial most cancers originates in urothelial cells, which line the urethra, bladder, ureters, renal pelvis and different organs. Also referred to as transitional cells, these cells can change form and stretch with out breaking up. This most cancers can be known as transitional cell most cancers.
Extra on the FDA Approval of This Mixture
Previous to the presentation on the assembly, on December 15, 2023, the FDA authorized Padcev with Keytruda for domestically superior or metastatic urothelial most cancers. The mix beforehand acquired accelerated approval for sufferers ineligible for cisplatin-based chemotherapy, in response to the FDA’s web site.
Approval was based mostly on the EV-302/KN-A39 trial, an open-label, randomized research of 886 sufferers with domestically superior or metastatic urothelial most cancers and no prior systemic remedy. Sufferers acquired both Padcev with Keytruda or platinum-based chemotherapy. The first endpoints had been general survival (OS) and PFS.
Padcev with Keytruda considerably improved OS (median 31.5 versus 16.1 months) and PFS (median 12.5 versus 6.3 months) in contrast with platinum-based chemotherapy.
Reference
“Neuropathy, pores and skin rash, and hyperglycemia as predictors of response to enfortumab vedotin in domestically superior and metastatic bladder and higher tract urothelial carcinoma.” By Dr. Salous T, et al. Introduced at: Poster Session 771
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
